Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9834539 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
US10532047 | RIGEL PHARMS INC | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(15 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11498913 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
US10414752 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
US10550098 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
US11376246 | RIGEL PHARMS INC | Inhibiting mutant IDH-1 |
May, 2039
(15 years from now) | |
US10959994 | RIGEL PHARMS INC | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(15 years from now) | |
US11013734 | RIGEL PHARMS INC | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
May, 2039
(15 years from now) | |
US11497743 | RIGEL PHARMS INC | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
May, 2039
(15 years from now) | |
US11013733 | RIGEL PHARMS INC | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
May, 2039
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 1, 2027 |
Orphan Drug Exclusivity (ODE) | Dec 1, 2029 |
Drugs and Companies using OLUTASIDENIB ingredient
NCE-1 date: 2026-12-01
Market Authorisation Date: 01 December, 2022
Treatment: A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation; A method of treating a cancer characterized by an idh1 mutation where the cancer is ac...
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8211889 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(2 years from now) | |
US7538108 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Mar, 2026
(2 years from now) | |
US7989448 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(2 years from now) | |
US8163902 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(2 years from now) | |
US7449458 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Sep, 2026
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9266912 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(2 years from now) | |
USRE48898 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jan, 2026
(2 years from now) | |
US9283238 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(2 years from now) | |
US8912170 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(2 years from now) | |
US8445485 | RIGEL PHARMS INC | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Jun, 2026
(2 years from now) | |
US8652492 | RIGEL PHARMS INC | Wet granulation using a water sequestering agent |
Nov, 2028
(5 years from now) | |
US8263122 | RIGEL PHARMS INC | Wet granulation using a water sequestering agent |
Nov, 2030
(7 years from now) | |
US8771648 | RIGEL PHARMS INC | (Trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(8 years from now) | |
US8951504 | RIGEL PHARMS INC | (trimethoxyphenylamino) pyrimidinyl formulations |
Jul, 2032
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 17, 2025 |
New Chemical Entity Exclusivity (NCE) | Apr 17, 2023 |
Drugs and Companies using FOSTAMATINIB DISODIUM ingredient
NCE-1 date: 2022-04-17
Market Authorisation Date: 17 April, 2018
Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic